“It’s a pharmaceutical company versus an insurer, and each is maneuvering to increase their profits. And we all understand their goals are to be profitable,” said Meghan McGarry. “It’s a battle about who makes the most money,” she told us. “And patients are being putting at risk.”
‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs
Previous
Previous
Non-White Newborns With Cystic Fibrosis More Likely To Be Missed in Screening
Next
Next